Introduction
muscle mass, gastrointestinal (GI) cancers, nausea, neutropenia, fatigue, cancer, sarcopenia, GI cancer, Sarcopenia, muscle loss, loss of skeletal muscle, Cancer
NEUTROPENIA, RECURRENT OVARIAN CANCER, CANCER, SARCOPENIA, GI CANCER, SARCOPENIA, CANCER
The loss of skeletal muscle, sarcopenia, has an exceptionally high prevalence in cancer patients, particularly in gastrointestinal (GI) cancers. The prevalence of sarcopenia in cancer patients before starting treatment is about 15–74% [Sarcopenia cannot be fully restored by traditional nutritional support [The exercise therapy approach has the advantage of reducing muscle loss due to chemotherapy and has been used to treat sarcopenia in several types of cancer. Mizrahi et al. reported an enrollment rate of 63% and an adherence rate of 81% after recurrent ovarian cancer patients receiving chemotherapy completed a 12-week exercise therapy program. There was a statistical improvement in the quality of life, fatigue, and muscle strength [Cancer patients have poor appetites, nausea and neutropenia due to chemotherapy and then they cannot exercise regularly. Cancer patients receiving cytotoxic chemotherapy may also have reduced muscle mass [The purpose of this study was to determine the compliance and attrition rate and the safety of an exercise treatment program in GI cancer patients during palliative chemotherapy. The results of this study can be used in planning future phase II trials since this study provides a reasonable estimate of the length, intensity and places of an exercise intervention program for patients undergoing chemotherapy.